U.S. markets open in 1 hour 47 minutes
  • S&P Futures

    4,381.75
    +33.50 (+0.77%)
     
  • Dow Futures

    34,119.00
    +280.00 (+0.83%)
     
  • Nasdaq Futures

    15,122.50
    +113.00 (+0.75%)
     
  • Russell 2000 Futures

    2,199.40
    +22.60 (+1.04%)
     
  • Crude Oil

    71.08
    +0.79 (+1.12%)
     
  • Gold

    1,766.90
    +3.10 (+0.18%)
     
  • Silver

    22.53
    +0.33 (+1.47%)
     
  • EUR/USD

    1.1745
    +0.0018 (+0.15%)
     
  • 10-Yr Bond

    1.3090
    0.0000 (0.00%)
     
  • Vix

    23.07
    +2.26 (+10.86%)
     
  • GBP/USD

    1.3681
    +0.0021 (+0.16%)
     
  • USD/JPY

    109.3850
    -0.0350 (-0.03%)
     
  • BTC-USD

    43,427.96
    -611.41 (-1.39%)
     
  • CMC Crypto 200

    1,088.75
    -45.63 (-4.02%)
     
  • FTSE 100

    6,980.79
    +76.88 (+1.11%)
     
  • Nikkei 225

    29,839.71
    -660.34 (-2.17%)
     

Catalyst Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CORAL GABLES, Fla., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will be presenting at the 22nd Annual BIO CEO & Investor Conference, which is being held on February 10-11, 2020 at the New York Marriott Marquis Hotel in New York City.

The presentation will occur on Tuesday, February 11th at 1:45 PM ET. The presentation materials will be posted at www.catalystpharma.com in the Investor section under Events and Presentations.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis (MuSK-MG) and spinal muscular atrophy (SMA) Type 3. Catalyst's new drug application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in November 2018 by the U.S. Food & Drug Administration ("FDA"), and Firdapse is now commercially available in the United States. Prior to its approval, Firdapse for LEMS had received breakthrough therapy designation and orphan drug designation from the FDA.

Firdapse is currently being evaluated in clinical trials for the treatment of MuSK-MG and SMA Type 3 and has received Orphan Drug Designation from the FDA for myasthenia gravis.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2018 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Investor Contact
Brian Korb
Solebury Trout
(646) 378-2923
bkorb@troutgroup.com

Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com

Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com